How Much Did Spear Bio Raise?
Funding & Key Investors

Spear Bio, a company focused on next-generation ultrasensitive immunoassay technology, has secured a significant strategic investment, adding to its total funding of $49M. The recent capital infusion, detailed as $45M, marks a pivotal moment for the Woburn, MA-based firm, underscoring its potential in the advanced diagnostics sector.

What is Spear Bio?

Spear Bio
Business ServicesResearch & Development

Founded in 2021 by former Harvard researchers Feng Xuan and Peng Yin, Spear Bio is dedicated to advancing ultrasensitive immunoassay technology. The company collaborates with academic researchers, clinicians, and industry partners to pioneer more sensitive detection methods and versatile assay approaches. These innovations aim to support non-invasive sample collection and enhance cutting-edge laboratory diagnostics, positioning Spear Bio at the forefront of diagnostic technology development.

How much funding has Spear Bio raised?

Spear Bio has raised a total of $49M across 2 funding rounds:

2021

Angel/Seed

$4M

2024

Series A

$45M

Angel/Seed (2021): $4M, investors not publicly disclosed

Series A (2024): $45M led by Foresite Capital and Bio-Techne

Key Investors in Spear Bio

Foresite Capital

Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data. The firm targets breakthrough opportunities at the intersection of technology and biotechnology, employing a data science-driven investment approach.

Bio-Techne

Founded in 1981, Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases.

What's next for Spear Bio?

The recent major strategic investment signals a strong validation of Spear Bio's technological advancements and market potential. This capital infusion is expected to accelerate the company's growth trajectory, enabling further research and development, scaling of operations, and broader market penetration. Spear Bio's focus on non-invasive diagnostics and ultrasensitive detection methods aligns with growing trends in personalized medicine and early disease detection, suggesting a promising future for the company as it seeks to revolutionize laboratory diagnostics.

See full Spear Bio company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Business Services industry

Business ServicesFood Service
Business ServicesHuman Resources Management Systems (HRMS)Project Management
Business ServicesSoftware TestingProject Management
Business ServicesHuman Resources Management Systems (HRMS)

Frequently Asked Questions Regarding Spear Bio Financial Insights

What are the most recent funding rounds that Spear Bio has completed, and what were the funding rounds?
Spear Bio has recently completed 2 funding rounds: Series A on Jul 28, 2024, Angel/Seed on Oct 13, 2021.
What is the total amount of funding Spear Bio has raised to date?
Spear Bio has raised a total of $49M in funding to date.
How many funding rounds has Spear Bio completed?
Spear Bio has completed 2 funding rounds.
How much funding did Spear Bio raise in its most recent funding round?
Spear Bio raised $45M in its most recent funding round.
Who are the lead investors in Spear Bio's latest funding round?
The lead investor in Spear Bio's latest funding round was Foresite Capital. To access investor data and explore similar companies, sign up for ZoomInfo.
Which was the largest funding round in Spear Bio's history?
The largest funding round in Spear Bio's history was $45M.
See more information about Spear Bio